Publications by authors named "I Lingvay"
SGLT-2i and GLP-1RA are recommended for persons with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) but are underused in clinical practice. The COORDINATE-Diabetes randomized clincal trial evaluated a multi-faceted intervention to increase the use of evidence-based therapies for reducing cardiovascular risk among participants with diabetes and atherosclerotic cardiovascular disease. This analysis reports the discontinuation rate of SGLT-2i and GLP-1RA in follow up and summarises the clinician-reported reasons underlying these decisions.
View Article and Find Full Text PDFOf the nearly 600,000 people in the U.S. who receive dialysis for chronic kidney failure, >60% have diabetes.
View Article and Find Full Text PDFArticle Synopsis
- Atherosclerotic cardiovascular disease is a major health concern for individuals with type 2 diabetes (T2D) and chronic kidney disease (CKD), but GLP-1 receptor agonists (GLP-1RAs) can help reduce cardiovascular risks, improve blood sugar levels, and promote weight loss despite low usage rates due to safety concerns.
- In a retrospective study involving 236 patients, those taking GLP-1RAs showed a significantly greater average weight loss (-9.6%) and better reduction in HbA1c levels (-1.0%) after 36 months compared to those on dipeptidyl-peptidase 4 inhibitors (DPP-4is), who lost only -2.4
Article Synopsis
- Researchers studied the effects of glucagon-like peptide-1 receptor agonists (GLP1-RA) versus Dipeptidyl peptidase-4 inhibitors (DPP4i) in U.S. veterans aged 35 and older with chronic kidney disease (CKD) and type 2 diabetes (T2D) from 2006 to 2021.
- They aimed to see how these treatments affected healthcare usage, mortality rates, and cardiovascular events.
- Results showed that GLP1-RA use led to lower healthcare utilization and all-cause mortality rates without a significant difference in cardiovascular events after a follow-up period of about 2.2 years.
Objective: Insulin icodec (icodec), a once-weekly basal insulin analog, has been investigated in the phase 3a ONWARDS clinical trial program. This pharmacokinetic (PK)/pharmacodynamic (PD) modeling analysis of data from the ONWARDS 2 and 4 trials investigated efficacy outcomes and hypoglycemia rate in insulin-experienced individuals with type 2 diabetes when switching from daily basal insulin to icodec without or with a 50% one-time additional dose for the first injection only.
Methods: Data from two randomized, 26-week, phase 3a trials of insulin-experienced individuals with type 2 diabetes on a basal (ONWARDS 2) or basal-bolus (ONWARDS 4) insulin regimen were used for PK/PD model development and validation.